share_log

Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) Large Institutional Owners Must Be Happy as Stock Continues to Impress, up 43% Over the Past Week

Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) Large Institutional Owners Must Be Happy as Stock Continues to Impress, up 43% Over the Past Week

Ventyx Biosciences, Inc.(納斯達克:VTYX)的主要機構投資者們一定很高興,因爲該股票持續給人留下深刻印象,上週上漲了43%。
Simply Wall St ·  11/27 18:12

Key Insights

主要見解

  • Given the large stake in the stock by institutions, Ventyx Biosciences' stock price might be vulnerable to their trading decisions
  • 53% of the business is held by the top 9 shareholders
  • Insiders have bought recently
  • 考慮到機構在該股票中持有大部分股份,Ventyx Biosciences的股價可能會受到他們的交易決策的影響。
  • 業務的53%由前9大股東持有。
  • 內部人士最近購買了股票。

To get a sense of who is truly in control of Ventyx Biosciences, Inc. (NASDAQ:VTYX), it is important to understand the ownership structure of the business. We can see that institutions own the lion's share in the company with 59% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

要了解真正控制Ventyx Biosciences, Inc. (NASDAQ:VTYX)的人是誰,重要的是了解公司的所有權結構。我們可以看到,機構擁有該公司59%的股份。換句話說,該團體將從對該公司的投資中獲益最多(或損失最多)。

And last week, institutional investors ended up benefitting the most after the company hit US$146m in market cap. One-year return to shareholders is currently 10% and last week's gain was the icing on the cake.

上週,機構投資者受益最多,因爲公司市值達到了14600萬美元。股東的一年回報率目前爲10%,上週的收益是錦上添花。

Let's delve deeper into each type of owner of Ventyx Biosciences, beginning with the chart below.

讓我們深入研究每種Ventyx Biosciences所有者的類型,從下面的圖表開始。

big
NasdaqGS:VTYX Ownership Breakdown November 27th 2024
納斯達克指數:VTYX 2024年11月27日的所有權拆分

What Does The Institutional Ownership Tell Us About Ventyx Biosciences?

關於Ventyx Biosciences的機構持股告訴我們什麼?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

機構通常在向自己的投資者報告時會針對一個基準進行衡量,因此一旦某隻股票被納入主要指數,他們通常會更加熱衷於該股票。我們預計大多數公司都會有一些機構在登記簿上,尤其是那些正在增長的公司。

As you can see, institutional investors have a fair amount of stake in Ventyx Biosciences. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Ventyx Biosciences' earnings history below. Of course, the future is what really matters.

正如您所見,機構投資者在Ventyx Biosciences中持有相當大比例的股份。這意味着爲這些機構工作的分析師已經研究了該股票並且他們喜歡它。但就像其他人一樣,他們也可能錯。如果多家機構同時改變對一隻股票的看法,那麼股價可能會快速下跌。因此,查看Ventyx Biosciences的歷史收入數據是值得的。當然,未來才是真正重要的。

big
NasdaqGS:VTYX Earnings and Revenue Growth November 27th 2024
納斯達克GS:VTYX盈利和營收增長2024年11月27日

Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. It would appear that 16% of Ventyx Biosciences shares are controlled by hedge funds. That catches my attention because hedge funds sometimes try to influence management, or bring about changes that will create near term value for shareholders. The company's largest shareholder is New Science Ventures, LLC, with ownership of 10%. In comparison, the second and third largest shareholders hold about 9.5% and 6.9% of the stock. Furthermore, CEO Raju Mohan is the owner of 2.4% of the company's shares.

投資者應注意,機構實際上擁有超過公司一半的股份,因此它們可以集體行使重要權力。看來Ventyx Biosciences股份的16%受到對沖基金的控制。這引起了我的注意,因爲對沖基金有時會試圖影響管理層,或提出改變,從而爲股東創造短期價值。該公司最大的股東是New Science Ventures,LLC,持有10%的股份。相比之下,第二和第三大股東持有約9.5%和6.9%的股份。此外,首席執行官Raju Mohan擁有公司股份的2.4%。

We did some more digging and found that 9 of the top shareholders account for roughly 53% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat.

我們進行了更深入的調查,發現前9大股東大約佔註冊股份的53%,這意味着除了較大的股東,還有一些較小的股東,從而在一定程度上平衡彼此的利益。

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

研究機構所有權是衡量和過濾股票預期表現的好方法。通過研究分析師的情緒也可以實現同樣的目的。由於有相當數量的分析師涵蓋這支股票,因此了解他們對未來的整體看法可能會有所幫助。

Insider Ownership Of Ventyx Biosciences

Ventyx生物科學的內部所有權

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

公司內部人員的定義可能是主觀的,並在不同的司法管轄區之間有所不同。我們的數據反映了個人內部人員,至少包括董事會成員。管理層最終向董事會負責。然而,經理們成爲執行董事會成員並不罕見,尤其是如果他們是創始人或首席執行官。

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

大多數人認爲內部所有權是積極的,因爲它可以表示董事會與其他股東的利益相一致。但是,在某些場合下,這個團體的權力過於集中。

We can see that insiders own shares in Ventyx Biosciences, Inc.. It has a market capitalization of just US$146m, and insiders have US$4.7m worth of shares, in their own names. It is good to see some investment by insiders, but we usually like to see higher insider holdings. It might be worth checking if those insiders have been buying.

我們可以看到,在Ventyx Biosciences,Inc.,內部持股。其市值僅爲14600萬美元,內部人士擁有470萬美元的股份,以自己的名義持有。看到內部人員進行一些投資是好事,但我們通常希望看到更高的內部持股。也許值得檢查這些內部人員是否一直在買入。

General Public Ownership

一般大衆所有權

With a 12% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Ventyx Biosciences. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

在Ventyx Biosciences擁有12%的股權,主要由個人投資者構成的普通大衆對其具有一定的影響力。儘管這種持股規模相當可觀,但如果決定與其他大股東不一致,可能還不足以改變公司政策。

Private Equity Ownership

股權投資公司持有8.8%的股份,有能力參與塑造以價值創造爲重點的公司策略。一些投資者可能會因此而受到鼓舞,因爲股權投資公司有時可以鼓勵市場看到公司的價值,從而採取有益的策略。另外,那些持有者可能在將其上市後退出投資。

With an ownership of 10%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.

擁有10%股權的股權投資公司有機會在塑造企業價值創造爲重點的戰略中發揮作用。有些人可能喜歡這種情況,因爲股權投資有時是活躍分子,追究管理層的責任。但有時,股權投資卻在出售股權,將公司推向公開市場。

Next Steps:

下一步:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. For example, we've discovered 4 warning signs for Ventyx Biosciences (1 shouldn't be ignored!) that you should be aware of before investing here.

儘管考慮公司的不同股東群體是值得的,但還有其他更重要的因素。 例如,我們發現了Ventyx Biosciences的4個警示信號(1個不容忽視!),在您投資這裏之前,您應該意識到這些。

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

最終,未來最重要。您可以在這份關於該公司分析師預測的免費報告中獲取有關信息。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注:本文中的數據是使用最後一個財務報表日期結束的爲期12個月的數據計算的。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論